App-Quantinova.ai

Reducing comorbidity coding errors in the costing of elective cardiac device implants

Yusuf Kiberu - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Investigating how often daily weights are recorded in acute heart failure patients on duiretic treatment

Anas Khan - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Could an increased focus on heart failure medications post icd crt d implant for primary prevention of sudden cardiac death reduce device therapy rates

Sami Al-Othman - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmogenic right ventricular cardiomyopathy

Albert

Utilisation of sodium glucose transport protein 2 sglt2 inhibitor in patients with cardiac resynchronisation therapy crt device a uk district general hospital perspective

Ronald Manorekang - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

BI-10773

Are we avoiding the american heart association list of medications which can cause or worsen heart failure a retrospective analysis on acute heart failure admissions

Theofanis Nizamis - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Uncovering mechanisms of obesity related heart failure using cardiovascular magnetic resonance imaging in the uk biobank

Liliana Szabo - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Empagliflozin in heart failure with a preserved ejection fraction 50 results from the emperor preserved clinical trial

Zaheer Yousef - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

BI-10773

The relation between change in left ventricular systolic function and subsequent mortality in patients with chronic heart failure

Oliver Brown - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Angiotensin II

An rer of 1 05 to signify a maximum test underestimates peak vo2 in patients referred for heart transplantation

Joshua Barnes - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Advanced heart failure

N/A

Risk of mortality in heart failure admissions in weekend and bank holidays

Sundas Tahir Masudi - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Artificial intelligence facilitates monitoring of patients with heart failure in the lancashire objective volume evaluation of leg oedema in heart failure pilot randomised cross over trial love hf

Reham Awad - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Medicines optimisation before discharge in patients admitted to hospital with heart failure

Joe Cuthbert - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Sacubitril/valsartan

Real world implementation of an evidence based home cardiac rehabilitation programme for people with heart failure and their caregivers findings from the scot reach hf study

Carrie Purcell - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

What are the effects of covid 19 on heart failure admission rates and mortality

Sundas Tahir Masudi - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Congestive heart failure

N/A

Automated device heart failure audit tools identify high risk sub optimally managed hf patients

Aman Sanghera - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

A 5 year single centre experience of managing patients with cardiorenal syndrome in the multi disciplinary cardiorenal clinic

Mithilesh Joshi - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiorenal syndrome

N/A

Real world outcomes of sglt2 inhibition in a hfref population

Patrick Savage - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

BI-10773

Early and rapid initiation of hfref pharmacotherapy a real world experience of a 4 drugs in 4 weeks strategy

Chokanan Thaitirarot - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

Angiotensin II

Outcomes of NT probnp assay measurements in suspected heart failure in primary and secondary care settings

Marilena Giannoudi - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Systolic dysfunction

N/A

An unusual presentation of cardiogenic shock successfully managed with mechanical circulatory support

Stavros Eftychiou - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiogenic shock

sodium bicarbonate

Filters

45280 Abstracts